Kallo Inc. - FORM 8-K - EX-99.2 - PRO FORMA FINANCIAL STATEMENTS - January 7, 2010

Attached files

file filename
8-K - DIAMOND TECHNOLOGIES INC. FORM 8-K FOR DECEMBER 11, 2009 - Kallo Inc.dti8k121109.htm
EX-99.1 - FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2009 AND YEARS ENDED DECEMBER 31, 2008 AND 2007 - Kallo Inc.rmtifin.htm
Exhibit 99.2
 
 Diamond Technologies
 Unaudited Pro Forma Balance Sheet
 (In US Dollars)
                         
                         
       
December 31, 2008
                         
       
Diamond
  
Rophe
  
 
        
       
Technologies
      
Pro Forma
  
Pro Forma
               
Adjustments
  
Consolidated
                         
Assets
                    
 
Current Assets
                    
   
Cash and cash equivalents
$
                    629
$
              300
$
                          -
  
 
$
                           929
 
Total Current Assets
  
                    629
  
              300
  
                          -
-
    
                           929
                         
 
Property and equipments, net
  
                 9,674
  
                   -
  
                          -
-
    
                        9,674
 
Goodwill
          
            1,649,700
  
 A
  
                 1,649,700
Total Assets
$
               10,303
$
              300
$
            1,649,700
-
  
$
                 1,660,303
                       
                               -
Liabilities & Shareholders' Equity
                  
                               -
 
Current Liabilities
                  
                               -
   
Accounts payable
$
                        -
$
  
$
 
    
$
                               -
   
Accrued liabilities and other payable
  
                 4,500
  
                   -
    
-
    
                        4,500
   
Accrued  Officers' Salaries
  
             150,000
              
                    150,000
 
Total Current Liabilities
  
             154,500
        
-
    
                    154,500
                         
 
Acquisition Costs payable
          
            1,200,000
  
 A
  
                 1,200,000
 
Total Liabilities
  
             154,500
      
            1,200,000
      
                 1,354,500
                         
Shareholders' Equity
                  
                               -
 
Preferred stock, $0.00001 par value;
                    
   
none issued and outstanding
                    
 
Common stock, $0.00001 par value; 100,000,000 authorized;
-
  
300
  
(300)
  
A
  
-
   
19,720,002 shares issued and outstanding, including 16,720,002
shares of common stock outstanding and 3,000,000 shares of
common stock issued as part of the acquisition of Rophe
Medical Technologies Inc.
 
 
 
167
      
 
 
 
30
  
 
 
 
A
  
 
 
 
197
 
Additional paid-in capital
  
             172,508
  
                   -
  
               449,970
  
A
  
                    622,478
 
Deficit Accumulated during the Development Stage
           (316,872)
              
                  (316,872)
 
Total Shareholders' Equity
  
           (144,197)
  
              300
  
               449,700
-
    
                    305,803
Total Liabilities & Shareholders' Equity
$
               10,303
$
              300
$
            1,649,700
-
  
$
                 1,660,303

 
 
Note 1- Basis of Presentation
 

The unaudited pro forma balance sheet as of December 31, 2008 is based on the unaudited financial statements as of December 31, 2008 for Diamond Technologies Inc. (the ““Company”” or ““we””).The unaudited pro forma balance sheet gives effect to the issuance of stock by the Company and the purchase of the assets of Rophe Medical Technologies Inc.    These unaudited pro forma financial statements are not necessarily indicative of the financial position or results of operations, which would have resulted if the stock issuance and asset purchase had actually occurred on those dates.

 
Note 2-Pro Forma Adjustments:

(A)           Reflects purchase of Rophe for $1,200,000cash, payable as defined in the agreement, and 3,000,000 shares of common stock valued at $0.15per share(last sale price available)
 
 
 
 
 
 
 
 Diamond Technologies
 Unaudited Pro Forma Balance Sheet
 (In US Dollars)
                         
       
September 30, 2009
                         
       
Diamond
  
Rophe
  
 
        
       
Technologies
      
Pro Forma
  
Pro Forma
               
Adjustments
  
Consolidated
Assets
                    
 
Current Assets
                    
   
Cash and cash equivalents
$
                    131
$
              300
$
                          -
  
 
$
                           431
 
Total Current Assets
  
                    131
  
              300
  
                          -
-
    
                           431
                         
 
Property and equipments, net
  
                 7,316
  
                   -
  
                          -
-
    
                        7,316
 
Goodwill
          
          1,649,700
  
 A
  
                 1,649,700
Total Assets
$
                 7,447
$
              300
$
            1,649,700
-
  
$
                 1,657,447
                       
                               -
Liabilities & Shareholders' Equity
                  
                               -
 
Current Liabilities
                  
                               -
   
Accounts payable
$
                        -
$
  
$
 
    
$
                               -
   
Accrued liabilities and other payable
  
                 6,796
  
                   -
    
-
    
                        6,796
   
Accrued  Officers' Salaries
  
             150,000
              
                    150,000
   
Due to officer/shareholder
  
               41,780
              
                      41,780
 
Total Current Liabilities
  
             198,576
        
-
    
                    198,576
                         
 
Acquisition Costs payable
                    
   
Current Liabilities
          
             500,000
  
 A
  
                    500,000
   
Long-term Liabilities
          
            700,000
  
 A
  
                    700,000
 
Total Acquisition Costs payable
          
           1,200,000
      
                 1,200,000
                         
 
Total Liabilities
  
             198,576
      
           1,200,000
      
                 1,398,576
                         
Shareholders' Equity
                  
                               -
 
Preferred stock, $0.00001 par value;
                    
   
none issued and outstanding
                    
 
Common stock, $0.00001 par value; 100,000,000 authorized;
 
-
  
 
300
  
 
(300)
  
 
A
  
                               -
   
19,720,002 shares issued and outstanding, including 16,720,002
shares of common stock outstanding and 3,000,000 shares of
common stock issued as apart of the acquisition of Rophe Medical Technologies Inc.
 
 
 
167
      
 
 
 
30
  
 
 
 
 A
  
 
 
 
197
 
Additional paid-in capital
  
             172,508
  
                   -
  
              449,970
  
 A
  
                    622,478
 
Deficit Accumulated during the Development Stage
         (363,804)
              
                  (363,804)
 
Total Shareholders' Equity
  
         (191,129)
  
              300
  
            449,700
-
    
                    258,871
Total Liabilities & Shareholders' Equity
$
                 7,447
$
              300
$
           1,649,700
-
  
$
                 1,657,447

 
Note 1- Basis of Presentation
 

The unaudited pro forma balance sheet as of September 30, 2009 is based on the unaudited financial statements as of September 30, 2009 for Diamond Technologies Inc. (the ““Company”” or ““we””).The unaudited pro forma balance sheet gives effect to the issuance of stock by the Company and the purchase of the assets of Rophe Medical Technologies Inc.    These unaudited pro forma financial statements are not necessarily indicative of the financial position or results of operations, which would have resulted if the stock issuance and asset purchase had actually occurred on those dates.

Note 2-Pro Forma Adjustments:

(A)    Reflects purchase of Rophe for $1,200,000cash, payable as defined in the agreement, and 3,000,000 shares of common stock valued at $0.15per share(last sale price available)
 
 
 
 
 
 
 
Diamond Technologies
  
Unaudited Pro Forma Statement of Operations
  
(In US Dollars)
  
                         
   
For the Year Ended December 31, 2008
  
   
 
                    
   
Diamond
    
Rophe
              
   
Technologies
    
 
    
Pro Forma
    
Pro Forma
  
   
 
    
 
    
Adjustments
    
Consolidated
  
                         
                         
 Revenue
                        
  Sales
   $ -     $ -     $ -     $ -  
  Cost of goods sold
     5,245       -       -       5,245  
 Gross Profit
     (5,245 )     -       -       (5,245 )
                                 
 Operating Costs and Exp
                             -  
 Selling expenses
     -       -       -       -  
 Depreciation
     -       -       -       -  
   Other general and administrative
     60,525       -       -       60,525  
 Merger costs
     -       -       -       -  
 Total General and administrative
     60,525       -       -       60,525  
                              -  
 Income from Operations
     (65,770 )     -       -       (65,770 )
                              -  
 Other Income (Expenses)
                             -  
 Interest income
     -       -       -       -  
 Interest expense
     -       -       -       -  
 Imputed interest
     -       -       -       -  
 Sundry income (expense), net
     -       -       -       -  
 Total other income (expenses)
     -       -       -       -  
                              -  
 Income before Income Taxes
     (65,770 )     -       -       (65,770 )
                              -  
 Income taxes
                     -       -  
                              -  
 Net Income
   $ (65,770 )   $ -     $ -     $ (65,770 )
 
 
 

 

 
 
 


Diamond Technologies
  
Unaudited Pro Forma Statement of Operations
  
(In US Dollars)
  
                         
   
For Period Ended September 30, 2009
  
   
 
                    
   
Diamond
    
Rophe
              
   
Technologies
    
 
    
Pro Forma
    
Pro Forma
  
   
 
    
 
    
Adjustments
    
Consolidated
  
                         
                         
 Revenue
                        
  Sales
   $ -     $ -     $ -     $ -  
  Cost of goods sold
     -       -       -       -  
 Gross Profit
     -       -       -       -  
                                 
 Operating Costs and Exp
                             -  
 Selling expenses
     -       -       -       -  
 Depreciation
     -       -       -       -  
   Other general and administrative
     21,721       -       -       21,721  
 Merger costs
     -       -       -       -  
 Total General and administrative
     21,721       -       -       21,721  
                              -  
 Income from Operations
     (21,721 )     -       -       (21,721 )
                              -  
 Other Income (Expenses)
                             -  
 Interest income
     -       -       -       -  
 Interest expense
     -       -       -       -  
 Imputed interest
     -       -       -       -  
 Sundry income (expense), net
     -       -       -       -  
 Total other income (expenses)
     -       -       -       -  
                              -  
 Income before Income Taxes
     (21,721 )     -       -       (21,721 )
                              -  
 Income taxes
                     -       -  
                              -  
 Net Income
   $ (21,721 )   $ -     $ -     $ (21,721 )
 
 
 
 


 
 
 
 
 
Diamond Technologies


 
Pro Forma Financial Information
 
On December 31, 2009, Rophe Medical Technologies Inc. (“Rophe”) entered into a share purchase agreement (the “Purchase Agreement”), with Diamond Technologies  (“the Company”)(“DT”) (formerly Printing Components, Inc.) and its shareholders.  Pursuant to the Purchase Agreement, DT agreed to pay $1,200, 000 in cash and agreed to issue an aggregate of 3 million shares of its common stock valued at $0.15 per share (the last available sale price) totaling $450,000  to the shareholders of Rophe and/or designees in exchange for all of the issued and outstanding shares of Rophe (the “Share Exchange”). 

The DT acquisition of Rophe includes its three key technologies. These are:
1 – Communicable and Infectious Diseases Information Management System or CID-IMS ©
2 – Mobile Medical Clinic©
3 – Clinical Care Globalization Technology TransCare ©

Each of these technologies will be spun off into a separate “project” with the goal of marketing and selling the technology to the wider medical marketplace.

The payment of $1,200, 000 to the shareholders of Rophe is per the following schedule:

1.  
$50,000.00 to be paid on January 30, 2010
2.  
$200,000.00  to be paid on March 31,2010
3.  
$250,000.00 to be paid on April 30,2010
4.  
$233,333.33 to be paid upon  launch of Project 1 –
a.  
Communicable and Infectious Diseases Information Management System
5.  
$233,333.33 to be paid on launch of Project 2 –
a.  
Mobile Medical Clinic
6.  
$233,333.33 to be paid on launch of Project 3 –
a.  
Clinical Care Globalization Technology

The term “launch” is defined to mean when each technology is made available to the marketplace and sales reach the $500,000 level generated in collected revenue.


The unaudited pro forma balance sheets below at December 31, 2008 and statements of operations for the year ended December 31, 2008, assume that the Purchase Agreement occurred at the beginning of the period presented. The Company believes the assumptions used provide a reasonable basis for presenting the significant effects directly attributable to such transactions. The pro forma financial results are presented for informational purposes only and are not intended to be indicative of either future results of the Company’s operations or results that might have been achieved had the transactions actually occurred since the beginning of the reporting period.
 
 
 
 
 

Stock widget

Investing forum

Kallo Inc. Reports

Also read